Market Overview

Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry


Dublin, July 30, 2018 (GLOBE NEWSWIRE) -- The "Organ-On-A-Chip Innovations Fueling Drug Screening Applications" report has been added to's offering.

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight into the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human-relevant per se but can mimic a wide variety of human functions such as breathing, heartbeats, peristalsis, menstruation, neuronal communication.

Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human-relevant systems.

The US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom, and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.

Key Topics Covered:

1. Executive Summary
1.1 Research Scope - Application of Organ-on-a-chip Technology in Drug Screening Process
1.2 Research Methodology - Core Value
1.3 Key Findings: Organ-on-a-chip Technology

2. Technology Snapshot
2.1 A Brief Overview of Organ-on-a-chip Functioning
2.2 Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes
2.3 Current Trends in the Organ-on-a-chip platform

3. Organ-on-a-chip Platforms
3.1 Heart-on-a-chip Platform
3.2 Liver-on-a-chip Platform
3.2.1 High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications
3.2.2 Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability
3.3 Lung-on-a-chip Platform
3.3.1 Lung-on-a-chip: Platform Overview, Application, Disadvantages, and Features
3.4 Kidney-on-a-chip Platform
3.4.1 Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges
3.5 Gut-on-a-chip/Intestine-on-a-chip Platform
3.5.1 Intestine- and Gut-on-a-chip Serve as Enhanced Study Models
3.5.2 Intestine- and Gut-on-a-chip: The Applications and the Challenges
3.6 Nerve-on-a-chip Platform
3.6.1 Evaluation of Neurotoxicity with the Nerve-on-a-chip platform
3.7 Muscle-on-a-chip Platform
3.7.1 Muscle-on-Chip Platform to Determine Long-term rug effects on Muscle Loss and Toxicity
3.7.2 Muscle-on-a-chipPhysiology, Features and Application Areas
3.8 Brain-on-a-chip Platform
3.8.1 Emulation of Human-Blood-Brain Barrier
3.9 Multi-Organ Chip Platforms
3.10 Human-on-a-chip Platform

4. Drivers and Challenges of Organ-Chip Technology
4.1 Drivers and Challenges Impact Chart of Organ-Chip Technology
4.2 Organ-on-a-chip Technology
4.3 Stem ell henotypes key to unlocking vast otential of Organ-chip Systems

5. Major Organ-on-a-chip Companies
5.1 A Well-defined and Robust Nerve-on-a-chip Platform
5.2 CN Bio- UK's Organ-chip Technology Pioneer
5.3 Emulate propelling Drug Screening and Development through their
5.4 Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems
5.5 Liver-on-a-chip platforms with High Biological Fidelity
5.6 Scaffold-free Human Relevant Liver-on-a-Chip Systems
5.7 Validated Research-ready Organ-chip Systems
5.8 Organ-Chips that facilitate High Throughput Screening
5.9 Precise Flow-controlled ParVivo Organ-Chip Systems
5.10 Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform
5.11 TissUse pioneering Human-on-a-Chip platform

6. Intellectual Property Landscape of Organ-on-a-chip Technology
6.1. Patent Research Scope and Concepts
6.2 Top 20 Patent Holders in the Organ-on-a-chip Platform
6.3 Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008-2018*
6.4 Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008-2017

7. Funding Landscape of Organ-on-a-chip Technology
7.1 Funding Strength of Organ-Chip Technology- Global View
7.2 Government Funding for Organ-on-a-chip Development
7.3 Venture Capitalist-based Investment Funding in the OOC Market
7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development

8. Growth Opportunities
8.1 Growth Opportunity 1: Personalized Medicine
8.2 Growth Opportunity 2: Animal Model Replacement
8.3 Growth Opportunity 3: Identification of Biomarkers
8.4 Determinants of Organ-on-a-chip Platform's Impact on Drug Screening Process

9. Appendix

For more information about this report visit

         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Drug Abuse Screening, Biomaterials 

Primary Logo

View Comments and Join the Discussion!

Latest Ratings

ADNTRBC CapitalDowngrades16.0
DLPHRBC CapitalDowngrades17.0
MTORRBC CapitalDowngrades19.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.